-
1 day ago | 
onclive.com | Courtney Flaherty
The ASCO Living Guidelines for stage IV non–small cell lung cancer (NSCLC) with driver alterations were updated in December 2024, making it more important than ever for oncologists to stay abreast of continually evolving treatment recommendations and effectively communicate these updates to patients, according to Fawzi F Abu Rous, MD.
-
2 days ago | 
onclive.com | Courtney Flaherty
Treatment with nadofaragene firadenovec-vncg (Adstiladrin) produced a high 3-month complete response (CR) rate of 75% in patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1; n = 20), according to initial results from an ongoing phase 3 trial (NCT05704244) in Japan.1 In this study, the safety and efficacy of nadofaragene firadenovec are being evaluated in 2 cohorts comprising those with CIS...
-
3 days ago | 
onclive.com | Courtney Flaherty
CommentaryArticleApril 21, 2025Supplements and Featured PublicationsMolecular Testing and Evolving Treatment Strategies in HR+/HER2– Advanced Breast CancerVolume1 Issue 1Author(s):Fact checked by:Sara M. Tolaney, MD, MPH, discusses the value of incorporating ctDNA monitoring of ESR1 mutations into routine management for HR-positive breast cancer.
-
3 days ago | 
onclive.com | Courtney Flaherty
Advances in treatment strategies for squamous cell carcinoma of the lung—including dual-targeting agents like ivonescimab (SMT112) and ongoing research on predictive biomarkers for immunotherapy response, and efforts to bolster the efficacy of first-line therapies—are offering new hope for improved treatment outcomes in this difficult-to-treat cancer subtype, according to Fawzi F Abu Rous, MD.
-
4 days ago | 
onclive.com | Courtney Flaherty
Expanding targeted therapy options in ALK- and EGFR-mutated non–small cell lung cancer (NSCLC) has complicated frontline decision-making, underscoring the importance of individualized treatment selection based on disease characteristics, toxicity profiles, and patient preferences, according to Isabel Preeshagul, DO, MBS. “These are all good options, and we are simply happy to have them.
-
6 days ago | 
onclive.com | Courtney Flaherty
Given the association of CCNE1 amplification and cyclin E1 overexpression with poor treatment outcomes in high-grade serous ovarian cancer and the limited treatment arsenal for platinum-resistant disease, the potential use of cyclin E1 overexpression as a predictive biomarker of response to azenosertib is an important therapeutic avenue warranting further investigation, according to Fiona Simpkins, MD.
-
6 days ago | 
onclive.com | Courtney Flaherty
Several FDA approvals have expanded the previously sparse small cell lung cancer (SCLC) treatment armamentarium, shifting the standard of care (SOC) beyond traditional chemotherapy and toward immunotherapy-based strategies in both limited-stage SCLC (LS-SCLC) and extensive-stage SCLC (ES-SCLC), according to Isabel Preeshagul, DO, MBS.
-
1 week ago | 
onclive.com | Courtney Flaherty
Given the absence of commercially available BCMA-directed CAR T-cell therapies for systemic light chain (AL) amyloidosis and diminishing therapeutic outcomes observed across successive lines in BCMA-pretreated multiple myeloma, the deep and durable responses observed with compassionate use of MDC-CAR-BCMA001 among heavily pretreated patients suggest that this investigational agent could address a significant unmet need, according to Kiavasch Mohammad Nejad Farid, MD.
-
1 week ago | 
onclive.com | Courtney Flaherty
Time-limited, minimal residual disease (MRD)–guided treatment with zanubrutinib (Brukinsa) plus venetoclax (Venclexta) and obinutuzumab (Gazyva) led to deep MRD responses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), including those with TP53 mutations and/or previous exposure to a BTK inhibitor or venetoclax.
-
1 week ago | 
onclive.com | Courtney Flaherty
Although the combination of an aromatase inhibitor (AI) and a CDK4/6 inhibitor remains the standard of care for frontline management of advanced hormone receptor (HR)–positive, HER2-negative breast cancer, an increasing reliance on molecular profiling and the lack of predictive tools to reliably stratify patients according to endocrine sensitivity continue to complicate treatment selection and sequencing in the second-line and beyond, particularly as more effective agents become available in...
